Given that chemical apoptosis inhibitors have already been tested in clinical studies in patients with NASH (Ratziu et al, 2012), pharmacological targeting of the necroptosis pathway might potentially have additive beneficial effects in a combinatory approach together with apoptosis inhibitors that do not specifically target Caspase-8 in these patients. Here, CASP8 is linked to metabolic dysfunction-associated steatohepatitis.